Clinical Effectiveness-Implementation Hybrid Type 2 Study on Home-Delivered Cabenuva for People Living With HIV Who Are Not Retained in Care - Trial NCT06062979
Access comprehensive clinical trial information for NCT06062979 through Pure Global AI's free database. This phase not specified trial is sponsored by Whitman-Walker Institute and is currently Not yet recruiting. The study focuses on HIV. Target enrollment is 180 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Whitman-Walker Institute
Timeline & Enrollment
N/A
Nov 01, 2023
Jun 30, 2025
Primary Outcome
4-month adherence rate
Summary
The purpose of this study is to assess adherence to home-delivered long-acting injectable
 rilpivirine/cabotegravir (Cabenuva) among people living with HIV enrolled in the Mobile
 Outreach Retention and Engagement (MORE) program at Whitman-Walker Health due to significant
 barriers to being retained in care; the MORE program provides supportive services including
 dedicated care navigation, transportation assistance, and mobile/home-delivered care. The
 investigators will examine the equivalence of treatment outcomes among patients receiving
 injectable treatment within the MORE program as compared to those of patients receiving
 Cabenuva in standard care at Whitman-Walker Health.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06062979
Non-Device Trial